The immunophenotypic stability of plasma cell myeloma by flow cytometry

International Journal of Laboratory Hematology

Volumn 33, Issue 5, 2011, Pages 483-491

  Spears, M D ^a   Olteanu, H ^a   Kroft, S H ^a   Harrington, A M ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Flow cytometry; Immunophenotype; Minimal residual disease; Plasma cell myeloma; Stability

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; LABORATORY TEST; LIGHT CHAIN; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

ADULT; AGED; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 80051926755     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2011.01317.x     Document Type: Article

References (29)

1. Alejandre M.E., Madalena L.B., Pavlovsky M.A., Facio M.L., Corrado C., Milone G., Bresciani P.D., Fraind S.A., Pavlovsky S. & Pizzolato M.A. (2010) Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience. Clinical Chemistry and Laboratory Medicine 48, 727-31.
2. Baer M.R., Stewart C.C., Dodge R.K., Leget G., Sule N., Mrozek K., Schiffer C.A., Powell B.L., Kolitz J.E., Moore J.O., Stone R.M., Davey F.R., Carroll A.J., Larson R.A. & Bloomfield C.D. (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97, 3574-80.
3. Bataille R., Jego G., Robillard N., Barille-Nion S., Haroussearu J.-L., Moreau P., Amiot M. & Pellat-Deceunynck C. (2006) The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 91, 1234-1240.
4. Cao W., Goolsby C.L., Nelson B.P., Singhal S., Mehta J. & Peterson L.C. (2008) Instability of immunophenotype in plasma cell myeloma. American Journal of Clinical Pathology 129, 926-33.
5. Chen W, Karandikar NJ, McKenna RW & Kroft SH. (2007) Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. American Journal of Clinical Pathology 127, 39-46.
6. Durie B.G., Harousseau J.L., Miguel J.S., Bladé J., Barlogie B., Anderson K., Gertz M., Dimopoulos M., Westin J., Sonneveld P., Ludwig H., Gahrton G., Beksac M., Crowley J., Belch A., Boccadaro M., Cavo M., Turesson I., Joshua D., Vesole D., Kyle R., Alexanian R., Tricot G., Attal M., Merlini G., Powles R., Richardson P., Shimizu K., Tosi P., Morgan G. & Rajkumar S.V., International Myeloma Working Group. (2006) International uniform response criteria for multiple myeloma. Leukemia 20, 1467-73.
7. Grogan TM, Van Camp B, Kyle RA, Muller-Hermelink HK & Harris NL. (2001) Plasma cell neoplasms. In: WHO Classification of Tumours. Pathology and Genetics of Haematopoietic and Lymphoid Tissues (eds ES Jaffe, NL Harris, H Stein & JW Vardiman), pp 142-5. IARC Press: Lyon.
8. Gupta R., Bhaskar A., Kumar L., Sharma A. & Jain P. (2009) Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. American Journal of Clinical Pathology 132, 728-32.
9. Harrington AM, Hari P & Kroft SH. (2009) Utility of CD56 immunohistochemistry in follow-up of plasma cell myeloma. American Journal of Clinical Pathology 132, 60-66.
10. Kobayashi S., Hyo R., Amitani Y., Tanaka M., Hashimoto C., Sakai R., Tamura T., Motomura S. & Maruta A. (2006) Four-color flow cytometric analysis of myeloma plasma cells. American Journal of Clinical Pathology 126, 908-15.
11. Kumar S., Rajkumar S.V., Kimlinger T., Greipp P.R. & Witzig T.E. (2005) CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 19, 1466-1470.
12. Lin P., Owens R., Tricot G. & Wilson C.S. (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. American Journal of Clinical Pathology 121, 482-8.
13. Mateo G., Montalban M.A., Vidriales M.-B., Lahuerta J.J., Mateos M.V., Gutierrez N., Rosinol L., Montejano L., Blade J., Martinez R., de la Rubia J., Diaz-Medizvilla J., Sureda A., Ribera J.M., Ojanguren J.M., de Arriba G., Palomera L., Terol M.J., Orfao A. & San Miguel J.F. (2008) Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. Journal of Clinical Oncology 26, 2737-44.
14. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL & Coupland RW. (2008) Plasma cell neoplasms. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds SH Swerdlow, E Campo & NL Harris et al.), pp. 202-8. Vol. IARC Press: Lyon.
15. Moreau P., Robillard N., Jego G., Pellat C., Le Gouill S., Thoumi S., Avet-Loiseau H., Harousseau J.L. & Bataille R. (2006) Lack of CD27 in myeloma delineates different presentation and outcome. British Journal Haematology 132, 168-70.
16. Moreaux J., Hose D., Reme T., Jourdan E., Hundemer M., Legouffe E., Moine P., Bourin P., Moos M., Corre J., Mohler T., De Vos J., Rossi J.F., Goldschmidt H. & Klein B. (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108, 4194-7.
17. Ocqueteau M., Orfao A., Garcia-Sanz R., Almeida J., Gonzalez M. & San Miguel J.F. (1996) Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. British Journal Haematology 95, 489-93.
18. Paiva B., Vidriales M.B., Cerveró J., Mateo G., Pérez J.J., Montalbán M.A., Sureda A., Montejano L., Gutiérrez N.C., García de Coca A., de Las Heras N., Mateos M.V., López-Berges M.C., García-Boyero R., Galende J., Hernández J., Palomera L., Carrera D., Martínez R., de la Rubia J., Martín A., Bladé J., Lahuerta J.J., Orfao A. & San Miguel J.F., GEM/PETHEMA Cooperative Study Groups. (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112, 4017-23.
19. Raiva B., Almeida J., Perez-Andres M., Mateo G., Lopez A., Rasillo A., Vidriales M.-B., Lopex-Berges M.-C., San Miguel J.F. & Orfao A. (2010) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry Part B: Clinical Cytometry 78B, 239-252.
20. Pellat-Deceunynck C & Bataille R. (2004) Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells, Molecules and Diseases 32, 293-301.
21. Raja KRM, Kovarova L & Hajek R. (2010) Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytomery in other plasma cell disorders. British Journal Haematology 149, 334-351.
22. Rawstron A.C., Davies F.E., DasGupta R., Ashcroft A.J., Patmore R., Drayson M.T., Owen R.G., Jack A.S., Child A.J. & Morgan G.J. (2002) Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 100, 3095-3100.
23. Rawstron A.C., Laycock-Brown G., Hale G., Davies F.E., Morgan G.J., Child J.A., Hillmen P. & Owen R.G. (2006) CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. Haematologica 91, 1577-8.
24. Rawstron A.C., Orfao A., Beksac M., Bezdickova L., Brooimans R.A., Bumbea H., Dalva K., Fuhler G., Gratama J., Hose D., Kovarova L., Lioznov M., Mateo G., Morilla R., Mylin A.K., Omedé P., Pellat-Deceunynck C., Perez Andres M., Petrucci M., Ruggeri M., Rymkiewicz G., Schmitz A., Schreder M., Seynaeve C., Spacek M., de Tute R.M., Van Valckenborgh E., Weston-Bell N., Owen R.G., San Miguel J.F., Sonneveld P. & Johnsen H.E., European Myeloma Network. (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93, 431-8.
25. Robillard N, Pellat-Deceunynck C & Bataille R. (2005) Phenotypic characterization of the human myeloma cell growth fraction. Blood 105, 4845-8.
26. San Miguel J.F., Almeida J., Mateo G., Blade J., Lopez-Berges C., Calallero D., Hernandez J., Moro M.J., Fernandez-Calvo J., Diaz-Mediavilla J., Palomera L. & Orfao A. (2002) Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing efficacy of different treatement strategies and predicting outcome. Blood 99, 1853-1856.
27. Sarasquete M.E., Garcia-Sanz R., Gonzalez D., Martinez J., Mateo G., Martinez P., Ribera J.M., Hernandez J.M., Lahuerta J.J., Orfao A., Gonzalez M. & San Miguel J.F. (2005) Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90, 1365-72.
28. Walters M., Olteanu H., Van Tuinen P. & Kroft S.H. (2010) CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukemia in this cytogenetic sub-group. British Journal Haematology 149, 292-3.
29. Zent C.S., Wilson C.S., Tricot G., Jagannath S., Siegel D., Desikan K.R., Munshi N., Bracy D., Barlogie B. & Butch A.W. (1998) Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 91, 3518-23.